Pancreatic Adenocarcinoma Therapeutics Market Size Analysis To 2019

Table Of Content:
Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Overview 9
2.1.1 Pancreatic Neuroendocrine Tumors 10
2.2 Pathophysiology 11
2.2.1 Inherited Disease 11
2.2.2 Somatic Mutations 11
2.3 Signs and Symptoms 12
2.4 Risk Factors 13
2.4.1 Smoking 13
2.4.2 Pancreatitis and Other Medical Conditions 13
2.4.3 Obesity 13
2.4.4 Infections 13
2.5 Diagnosis 13
2.6 Treatment Algorithm 14
2.6.1 Surgery 14
2.6.2 Radiation Therapy 14
2.6.3 Chemotherapy 15
2.6.4 Algorithm of Chemotherapeutic Treatment for Pancreatic Cancer 16
Browse All Reports of This Category @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
3 Marketed Products 33
3.1 Approved Products 33
3.1.1 Gemcitabine 33
3.1.2 IV Fluorouracil 34
3.1.3 Tarceva 34
3.1.4 Abraxane 35
3.1.5 Teysuno/TS-1 36
3.2 Off-Label Products 36
3.2.1 Xeloda 36
3.2.2 Eloxatin 37
3.3 Marketed Products - Discussion 37
4 Product Pipeline 39
4.1 Pipeline Overview 39
4.2 Overview of Pipeline by Phase, Route of Administration, Molecule Type and Molecular
Target 39
4.3 Key Trends in Drug Development within the Pancreatic Cancer Pipeline 44